<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03343873</url>
  </required_header>
  <id_info>
    <org_study_id>2017-7-17</org_study_id>
    <nct_id>NCT03343873</nct_id>
  </id_info>
  <brief_title>The Effects of Different Anesthetics on Functional Connectivity and (EEG)</brief_title>
  <acronym>ACTION</acronym>
  <official_title>The Effects of Different Anesthetics on Functional Connectivity and Electroencephalogram (EEG) in Volunteers and Patients With Brain Tumor：A Double-Blinded, Randomized Controlled Trial (ACTION)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is a prospective double-blinded randomized controlled study. It will mainly
      discuss the mild sedative mechanism and the effect on brain functional connectivity and
      simultaneous EEG of midazolam, dexmedetomidine, propofol and ketamine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research will include 150 healthy volunteers and 150 brain tumor patients; the
      participants will be randomly divided into midazolam, dexmedetomidine, propofol, ketamine and
      saline (control) group. Resting and task fMRI will be performed with 32-leads EEG
      simultaneously at awake, sedation and recovery states. The primary outcome of our study is
      the effect of mild sedation for visual and auditory brain network connection. The secondary
      outcomes are the effect of mild sedation for default, executive control, sensory and motor
      networks and their subnetwork connectivity; the effect of mild sedation for simultaneous EEG;
      the sedation state, circulatory and respiratory parameters of the participants, and the
      adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amplitude of Low Frequency Fluctuations（ALLF）and Regional Homogeneity（ReHo)</measure>
    <time_frame>30mins after administration</time_frame>
    <description>The differences of amplitude of low frequency fluctuations (ALFF/Low Frequency Amplitude) and regional homogeneity（ReHo) in brain voxel - wise under anesthetic sedations.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>Midarolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>midarolam sensation group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>propofol sensation group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ketamine sensation group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dexmedetomidine sensation group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam was administered intravenously at a dose of 0.1 mg / kg followed by continuous intravenous injection at 0.03 mg / kg / h and maintained until the course of the scan.</description>
    <arm_group_label>Midarolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol group 1mg / kg intravenous injection, followed by 2mg / kg / h continuous intravenous injection, and maintained to the scanning process;</description>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>ketamine group with a bolus dose of 1mg / kg intravenous injection , followed by 10μg / kg / min continuous intravenous injection, and maintained to the scanning process;</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine group with total amount of 1μg / kg, infusion time 15min, followed by 0.6μg / kg / h, and maintained to the scanning process;</description>
    <arm_group_label>dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline group at 5ml / kg / h continuous intravenous infusion.</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Male, 18 ~ 45 years old

          -  2. Healthy Volunteer / Brain Tumor Patients

          -  3. High school and above

          -  4. Sign informed consent

        Exclusion Criteria:

          -  1. In vivo implant MRI check taboo

          -  2. Cardiopulmonary liver and kidney and other systemic complications

          -  3. History of major surgical anesthesia

          -  4. Abuse of drugs, alcoholism history

          -  5. Test drug allergy history

          -  6. Claustrophobia

          -  7. Left hand
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruquan Han, M.D., Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anesthesiology, Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruquan Han, M.D., Ph.D</last_name>
    <phone>8610-67096660</phone>
    <email>ruquan.han@gmail.com</email>
  </overall_contact>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>November 14, 2017</last_update_submitted>
  <last_update_submitted_qc>November 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Yuming Peng</investigator_full_name>
    <investigator_title>associated professor</investigator_title>
  </responsible_party>
  <keyword>anesthetics; fMRI; EEG; functional connectivity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

